View Future GrowthGenesystem 과거 순이익 실적과거 기준 점검 0/6Genesystem 의 수입은 연평균 -7.5%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 17.5%의 비율로 증가했습니다. 매출은 연평균 68.9%의 비율로 감소해 왔습니다.핵심 정보-7.55%순이익 성장률-8.35%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률-68.92%자기자본이익률-189.34%순이익률-3,134.97%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • May 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 68% over the past year. Revenue is less than US$1m (₩381m revenue, or US$259k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₩42.5b market cap, or US$28.8m).공시 • Mar 10Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2026Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 200-9, techno 2-ro, yuseong-gu, daejeon South Korea공시 • Feb 10Genesystem Co., Ltd. announced that it expects to receive KRW 6.00000782 billion in fundingGenesystem Co., Ltd. announced a private placement to issue 1,430,276 common shares at an issue price of KRW 4,195 for gross proceeds of KRW 6,000,007,820 on February 9, 2026. The transaction includes participation from new investor, H Fund. The transaction has been approved by the board of directors of the company. The payment date of 715,138 shares is March 31, 2026 and the payment date of 715,138 shares is February 27, 2026. The transaction will happen through third party allocation. The transaction is subject to 1 year lock-up.New Risk • Nov 27New major risk - Revenue and earnings growthRevenue has declined by 70% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.8b free cash flow). Revenue has declined by 70% over the past year. Revenue is less than US$1m (₩345m revenue, or US$236k). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩34.7b market cap, or US$23.7m).분석 기사 • Nov 26Is Genesystem (KOSDAQ:363250) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Revenue is less than US$1m (₩1.1b revenue, or US$818k). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₩36.4b market cap, or US$26.2m).분석 기사 • Jun 30Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Revenue is less than US$1m (₩1.1b revenue, or US$827k). Minor Risk Market cap is less than US$100m (₩67.2b market cap, or US$48.9m).New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩73.6b market cap, or US$50.0m).공시 • Mar 13Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2025Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 200-9, techno 2-ro, yuseong-gu, daejeon South KoreaNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 78% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩1.6b revenue, or US$1.1m). Market cap is less than US$100m (₩69.6b market cap, or US$47.7m).New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩1.6b revenue, or US$1.1m). Market cap is less than US$100m (₩76.8b market cap, or US$52.3m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 78% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (₩1.6b revenue, or US$1.1m). Market cap is less than US$100m (₩45.0b market cap, or US$32.6m).New Risk • Mar 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 78% over the past year. Minor Risks Revenue is less than US$5m (₩1.6b revenue, or US$1.2m). Market cap is less than US$100m (₩51.3b market cap, or US$38.3m).분석 기사 • Feb 28Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Oct 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 80% over the past year. Minor Risks Revenue is less than US$5m (₩1.9b revenue, or US$1.4m). Market cap is less than US$100m (₩86.7b market cap, or US$64.1m).New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩133.6b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 80% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$5m (₩1.9b revenue, or US$1.4m). Market cap is less than US$100m (₩133.6b market cap, or US$99.0m).Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩10,700, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 46% over the past year.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩11,700, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea.매출 및 비용 세부 내역Genesystem가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A363250 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 25381-11,9553,6702,68930 Sep 25345-8,9433,7302,90730 Jun 251,059-8,6343,8203,06031 Mar 251,136-8,5233,8723,06831 Dec 241,208-8,9153,9013,34430 Sep 241,152-7,5003,8403,43230 Jun 24552-8,0614,0643,52031 Mar 24559-7,9074,0163,28731 Dec 23897-7,9154,0743,42531 Dec 223,653-8,9964,1583,354양질의 수익: A363250 은(는) 현재 수익성이 없습니다.이익 마진 증가: A363250는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 A363250의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A363250의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A363250은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(25.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A363250는 현재 수익성이 없으므로 자본 수익률이 음수(-189.34%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 17:36종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genesystem Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • May 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 68% over the past year. Revenue is less than US$1m (₩381m revenue, or US$259k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₩42.5b market cap, or US$28.8m).
공시 • Mar 10Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2026Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 200-9, techno 2-ro, yuseong-gu, daejeon South Korea
공시 • Feb 10Genesystem Co., Ltd. announced that it expects to receive KRW 6.00000782 billion in fundingGenesystem Co., Ltd. announced a private placement to issue 1,430,276 common shares at an issue price of KRW 4,195 for gross proceeds of KRW 6,000,007,820 on February 9, 2026. The transaction includes participation from new investor, H Fund. The transaction has been approved by the board of directors of the company. The payment date of 715,138 shares is March 31, 2026 and the payment date of 715,138 shares is February 27, 2026. The transaction will happen through third party allocation. The transaction is subject to 1 year lock-up.
New Risk • Nov 27New major risk - Revenue and earnings growthRevenue has declined by 70% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.8b free cash flow). Revenue has declined by 70% over the past year. Revenue is less than US$1m (₩345m revenue, or US$236k). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩34.7b market cap, or US$23.7m).
분석 기사 • Nov 26Is Genesystem (KOSDAQ:363250) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Revenue is less than US$1m (₩1.1b revenue, or US$818k). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₩36.4b market cap, or US$26.2m).
분석 기사 • Jun 30Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Revenue is less than US$1m (₩1.1b revenue, or US$827k). Minor Risk Market cap is less than US$100m (₩67.2b market cap, or US$48.9m).
New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩73.6b market cap, or US$50.0m).
공시 • Mar 13Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2025Genesystem Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 200-9, techno 2-ro, yuseong-gu, daejeon South Korea
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 78% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩1.6b revenue, or US$1.1m). Market cap is less than US$100m (₩69.6b market cap, or US$47.7m).
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩1.6b revenue, or US$1.1m). Market cap is less than US$100m (₩76.8b market cap, or US$52.3m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 78% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (₩1.6b revenue, or US$1.1m). Market cap is less than US$100m (₩45.0b market cap, or US$32.6m).
New Risk • Mar 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 78% over the past year. Minor Risks Revenue is less than US$5m (₩1.6b revenue, or US$1.2m). Market cap is less than US$100m (₩51.3b market cap, or US$38.3m).
분석 기사 • Feb 28Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Oct 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 80% over the past year. Minor Risks Revenue is less than US$5m (₩1.9b revenue, or US$1.4m). Market cap is less than US$100m (₩86.7b market cap, or US$64.1m).
New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩133.6b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 80% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$5m (₩1.9b revenue, or US$1.4m). Market cap is less than US$100m (₩133.6b market cap, or US$99.0m).
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩10,700, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 46% over the past year.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩11,700, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea.